Related Experiment Video
Updated: Aug 20, 2026
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Identification of protein modulation by the synthetic retinoid CD437 in lung carcinoma cells using high throughput
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
The novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) induces growth arrest and apoptosis in various tumor cell lines including non-small cell lung cancer (NSCLC) cells. CD437 binds retinoic acid receptor gamma (RARgamma) selectively, and can enhance receptor-dependent transcriptional activation of various genes. However, some of the effects of this retinoid on cell growth inhibition and apoptosis appear to be receptor-independent. To gain a better understanding of the mechanism by which CD437 exerts its effects, we employed a high throughput western blotting method (PowerBlottrade mark) using 760 monoclonal antibodies to compare the levels of their target cellular signaling proteins in untreated and CD437-treated NSCLC H460 cells. CD437 (1 microM, 24 h) increased the levels of 70 proteins and decreased the levels of 28 proteins. These proteins play a role in fundamental cellular processes including: DNA synthesis and repair, transcription and DNA-binding, cell cycle, apoptosis, cytoskeleton assembly, cell adhesion, endocytosis, growth and signal transduction. Some proteins identified by this approach have been implicated previously in the effect of CD437 (e.g., p53, Bax, cyclin B, CDK2). Additionally we identified proteins that are novel candidates for mediating the cellular responses to CD437 (e.g., FAF1, Bid, caspase 8, cdk1, KAP, NDR, RBBP, 53BP2, Grb2, PLCgamma1, p70s6k, PP2Cdelta, PKBalpha/AKT, PDK1, and several DNA repair enzymes).
Insights
The synthetic retinoid CD437 halts tumor cell growth and induces apoptosis in non-small cell lung cancer (NSCLC) cells. This study identified numerous proteins involved in CD437
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The synthetic retinoid CD437 demonstrates anti-cancer properties, inducing growth arrest and apoptosis in cancer cells, including non-small cell lung cancer (NSCLC).
- CD437 selectively binds retinoic acid receptor gamma (RARgamma), influencing gene transcription, but some effects suggest receptor-independent mechanisms.
- Understanding the precise molecular mechanisms of CD437's action is crucial for its therapeutic development.
Purpose of the Study:
- To elucidate the mechanism of action of CD437 in NSCLC cells.
- To identify cellular signaling proteins modulated by CD437 treatment.
- To uncover novel protein candidates involved in CD437-mediated cellular responses.
Main Methods:
- Utilized a high-throughput western blotting technique (PowerBlot™) with 760 monoclonal antibodies.
- Compared protein expression levels in untreated and CD437-treated NSCLC H460 cells.
- Analyzed changes in proteins involved in key cellular processes.
Main Results:
- CD437 treatment (1 µM, 24 h) significantly altered the levels of 98 proteins (70 increased, 28 decreased).
- Affected proteins are involved in DNA synthesis/repair, transcription, cell cycle, apoptosis, cytoskeleton, cell adhesion, endocytosis, growth, and signal transduction.
- Confirmed known CD437-related proteins (e.g., p53, Bax) and identified novel candidates (e.g., FAF1, Bid, caspase 8, AKT).
Conclusions:
- CD437 modulates a broad spectrum of cellular signaling proteins in NSCLC cells.
- Both known and novel proteins are implicated in CD437's anti-cancer effects, suggesting complex receptor-dependent and -independent pathways.
- The identified proteins offer new targets for understanding and potentially enhancing CD437's therapeutic efficacy in NSCLC.
